Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2024-01-11 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
独立董事候选人声明与承诺_刘娅
Board/Management Information Classification · 95% confidence The document is a detailed declaration and commitment statement by an independent director candidate for a listed company, confirming compliance with various legal and regulatory requirements for independent directors. It includes personal affirmations about qualifications, independence, and adherence to relevant laws and stock exchange rules. This type of document is related to board or management information, specifically concerning the nomination and qualifications of a board member. It is not a financial report, earnings release, or regulatory filing about financial performance. It is also not a proxy solicitation or voting result announcement. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is about 5030 characters, which is consistent with a detailed declaration rather than a brief announcement or report publication notice.
2024-01-11 Chinese
第二届监事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolution from the 18th meeting of the second Supervisory Board of Enwei Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the proposal for the election of the third Supervisory Board members. It references compliance with company law and regulatory guidelines, and mentions that the proposal will be submitted to the upcoming shareholders' meeting for approval. The document is a formal announcement of board/management changes related to the Supervisory Board election process, not a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a report publication or regulatory filing. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board resolutions and nominations, confirming this classification with high confidence.
2024-01-11 Chinese
关于召开2024年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2024 first extraordinary general meeting (临时股东大会) of Enwei Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be voted on (including board and supervisory board elections), registration details, and proxy forms. The content focuses on the organization and conduct of a shareholders' meeting, including election of directors and supervisors, voting methods, and meeting logistics. There is no financial data, earnings information, or audit content. The document is not a report itself but a formal meeting notice and related materials for shareholders to participate and vote. This fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document length is sufficient and contains substantive meeting information, not just a brief announcement or link to a report, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is AGM-R with high confidence.
2024-01-11 Chinese
提名与薪酬委员会工作制度
Governance Information Classification · 95% confidence The document is titled '董事会提名与薪酬委员会工作制度' which translates to 'Board Nomination and Remuneration Committee Working System'. It details the structure, responsibilities, and procedures of the board's nomination and remuneration committee, including rules for director and senior management nominations, assessments, and compensation policies. There are no financial statements, earnings data, or regulatory filings. The content focuses on governance practices related to board and management compensation and nomination processes. This fits the definition of Governance Information (CGR), which covers internal rules, board structure, and governance practices. The document length is 2272 characters, which is consistent with a detailed governance policy document rather than a brief announcement or a full annual report.
2024-01-11 Chinese
战略与发展委员会工作制度
Governance Information Classification · 95% confidence The document is titled as the 'Board of Directors Strategic and Development Committee Work System' for Enwei Pharmaceutical Co., Ltd., detailing the committee's composition, responsibilities, meeting rules, and governance structure. It is a governance-related internal regulation document, not a financial report, announcement, or meeting material. It does not contain financial data, voting results, or executive changes. It fits the category of Governance Information (CGR) as it outlines the company's internal governance practices and board committee rules.
2024-01-11 Chinese
独立董事工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' (Independent Director Work System) and details the governance structure, qualifications, duties, nomination, election, and protections of independent directors at 恩威医药股份有限公司. It references relevant laws, regulations, and stock exchange rules, and is dated January 2024. The content is a governance policy document outlining internal rules and procedures for independent directors rather than a financial report, announcement, or meeting material. It does not contain financial statements, voting results, or executive changes. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-01-11 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.